TechNavio recognizes the following companies as the key players in the Global Epigenetics Market: Celgene Corp., Eisai Inc., and Merck & Co. Inc.
Commenting on the report, an analyst from TechNavio’s team said: “Along with oncology indications, epigenetic drugs also find application in non-oncology indications such as inflammatory diseases, autoimmune diseases, neurodegenerative disorders, and personalized medicine. These are some of the high growth and emerging areas that are expected to drive the Global Epigenetics market in the future. Current treatments for chronic and degenerative disorders are in many cases inadequate or very expensive. Epigenetic drugs are attractive options for treating such disorders because they manipulate the processes that maintain cells in an abnormal transcriptional state.”
According to the report, one of the main drivers propelling the growth of the market is the steadily growing aging population worldwide. There is a strong correlation between cancer and aging. The number of patients suffering from cancer is increasing owing to the increasing aging population, both in developing and developed nations.
Further, the report states that one of the major challenges faced by the market is the patent expiries of major drugs. Patent expiries erode the revenue potential of the market and affect the market negatively.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit https://www.technavio.com/report/global-epigenetics-market-2014-2018
TechNavio, the market research platform of Infiniti Research Ltd., publishes periodic market research reports on niche and emerging technologies. For more information on our market research, please visit https://www.technavio.com/healthcare-chemicals-food-retail
Follow us on Twitter @ Technavio